ZVRA · Zevra Therapeutics, Inc.

The thesis

Zevra Therapeutics has a narrow recovery case that rests on US sales of MIPLYFFA (arimoclomol, its Niemann-Pick disease type C drug) rising above the $30.2 million reported for Q2 2026. The Q3 report, due after the market close on 3 November 2026, settles that; the European Medicines Agency (EMA) re-examination, which the company guides to Q4 2026, settles Europe.

The adjusted close was $9.81 on 23 October 2026, 33.5% below the 52-week high of $14.75. The shares closed at $11.39 on 9 October 2026, and the 14-day relative strength index (RSI) has fallen from 46.4 then to 37.5. The narrative is maturing: the 5 August 2026 Q2 report and the July EMA opinion are well known, the shares have not approached the high since, and the next fresh information arrives with the Q3 report. The three-month price change is 0.8%.

Bullish and bearish views on Zevra Therapeutics, Inc.

The bull case on Zevra Therapeutics, Inc. (ZVRA), in brief: US sales are growing. The bear case: Europe is an efficacy dispute.

Bull case

• US sales are growing. Zevra reported MIPLYFFA net revenue of $30.2 million for Q2 2026 on 5 August 2026, against $24.6 million in Q1 2026. A Q3 figure above $30.2 million would extend that trend.
• Balance sheet carries no debt. The Q2 release put cash, equivalents and investments at $260.2 million on 30 June 2026 and Q2 net income at $8.8 million. Zevra repaid $61.9 million of debt in March 2026.
• Analyst targets sit far above the price. StockAnalysis listed a 12-month average target of $25.0 from nine analysts on 11 October 2026, including Citizens at $28, Wainwright at $26, Guggenheim at $23 and Roth MKM at $21. Several of these targets predate the July EMA opinion.
• Europe is not closed. Zevra requested re-examination of the negative opinion from the CHMP (the EMA's drug-evaluation committee) dated 24 July 2026. It cites long-term, pediatric, expanded-access and safety data and expects a decision in Q4 2026.

Bear case

• Europe is an efficacy dispute. The EMA said on 24 July 2026 that efficacy had not been sufficiently demonstrated and found the miglustat subgroup result insufficiently robust. A final opinion repeating that conclusion would end the European approval path.
• Revenue mix flatters the total. Of $39.7 million in Q2 2026 net revenue, $30.2 million was MIPLYFFA and $9.0 million was expanded-access reimbursement, per the 5 August 2026 release. Total revenue alone is a weak test of US product demand.
• The patient pool is small. Zevra reported 14 new prescription enrollment forms in Q2 2026 and 184 cumulative since the September 2024 launch, with payer coverage at 69% of covered lives. One quarter of additions is too small a sample to show acceleration or saturation.
• One product carries the company. MIPLYFFA was $30.2 million of $39.7 million Q2 net revenue, so a US stall would hit nearly all of the revenue base.

Price setup

The adjusted close on 23 October 2026 was $9.81. The 52-week high is $14.75 and the 52-week low is $7.16. The shares closed at $11.39 on 9 October 2026, so the recovery noted in the prior update has reversed. No company news explaining the decline is listed for the period; the only item is the 20 October 2026 announcement of the Q3 call details.

RSI of 37.5 is lower than the 46.4 reading of 9 October 2026 and above the 23.1 reading of 25 September 2026. The invalidation level of $9.47 sits 3.5% under the latest close, so the shares are close to it going into the report.

Crowding evidence is limited. The Q3 report is 11 days away, which concentrates the risk in one event. Recent SEC filings listings show no insider transactions or share issuance, and no retail-attention data is available for the period.

Catalysts, next 30 days

• ~31 December 2026 (est.): EMA re-examination outcome. Zevra guides to Q4 2026, and no date has been confirmed. It falls outside the 30-day window but the European half of the case turns on it.

Elapsed catalysts

• 3 November 2026: Q3 2026 results. Zevra reports after the close with a call at 4:30 p.m. ET, per its 20 October 2026 release. The test is MIPLYFFA net revenue against $30.2 million, new enrollment forms against 14, and expanded-access reimbursement against $9.0 million. (passed 3d ago)

What would change the view

The case breaks if Q3 2026 MIPLYFFA net revenue comes in at or below the $30.2 million reported for Q2, or if the EMA's final re-examination opinion repeats the 24 July 2026 efficacy conclusion. A daily close below $9.47 would also end it, extending the decline from the $11.39 close of 9 October 2026.

The case strengthens if MIPLYFFA revenue rises while expanded-access reimbursement stays near or below $9.0 million, which would show commercial demand rather than access-program billing driving the total. A reversal at the EMA would reopen the European market.

What it trades with

Zevra trades on company-specific events, a US launch and a European regulatory decision, more than on sector moves. Small-cap rare-disease biotech names tend to move together when risk appetite shifts, but no measured correlation figure is available for this note. The shares fell about 24% on 24 July 2026 on the EMA opinion alone.